ProQR Therapeutics (PRQR) Cash from Restructuring (2019)

ProQR Therapeutics (PRQR) posted Cash from Restructuring of -$322484.4 for Q2 2019.

ProQR Therapeutics (PRQR) Cash from Restructuring (2019) Analysis & Trends

ProQR Therapeutics has reported Cash from Restructuring for 1 years, with the latest figure at -$322484.4 in Q2 2019.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 ProQR Therapeutics 206.80 Mn 111.86 Mn -

Historic Data

Download Data
DateValue
Jun 30, 2019 -322,484.42